ACOG

Alpha Cognition Inc

8.31

Oct 22 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: AVXL AXSM CGTX ANVS ACAD PRTA INMB ATHE ALZN SUPN

Index	-
Market Cap	180.97M
Enterprise Value	139.53M
Income	-23.44M
Sales	15.26M
Book/sh	2.43
Cash/sh	1.90
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	71
IPO	Jun 28, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	11.86
P/B	3.42
P/C	4.37
P/FCF	-
EV/EBITDA	-
EV/Sales	9.14
Quick Ratio	8.00
Current Ratio	9.00
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.12
EPS next Y	-0.62
EPS next Q	-0.34
EPS this Y	-12.68%
EPS next Y	53.22%
EPS next 5Y	-
EPS past 3/5Y	35.73% 45.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	31.08%
Sales Y/Y TTM	232.74%
EPS Q/Q	38.34%
Sales Q/Q	267.56%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-2.01% 36.86%

Insider Own	8.37%
Insider Trans	80.24%
Inst Own	83.06%
Inst Trans	-2.33%
ROA	-42.76%
ROE	-55.25%
ROIC	-44.26%
Gross Margin	89.24%
Oper. Margin	-190.62%
Profit Margin	-153.61%
SMA20	-4.90%
SMA50	-7.13%
SMA200	17.46%
Trades

Shs Outstand	21.77M
Shs Float	14.23M
Short Float	2.27%
Short Ratio	2.58
Short Interest	0.32M
52W High	10.14 -18.05%
52W Low	4.50 84.67%
Volatility	6.24% 5.58%
ATR (14)	0.49
RSI (14)	40.45
Beta	2.34
Rel Volume	0.00
Avg Volume	125.18K
Volume	0

Perf Week	-1.66%
Perf Month	-5.35%
Perf Quarter	5.19%
Perf Half Y	21.31%
Perf YTD	27.85%
Perf Year	20.43%
Perf 3Y	15.86%
Perf 5Y	-69.05%
Perf 10Y	-
Recom	1.20
Target Price	18.00
Prev Close	8.31
Price	8.31
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-26	Initiated	B. Riley Securities	Buy	$21
Jul-10-26	Initiated	Raymond James	Outperform	$20
May-29-26	Initiated	Maxim Group	Buy	$12
Apr-17-26	Initiated	Craig Hallum	Buy	$14
Mar-18-25	Initiated	H.C. Wainwright	Buy	$20

Oct-13-26 08:30AM	Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL (Business Wire)
Oct-06-26 08:30AM	Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress (Business Wire)
Oct-02-26 07:06PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-01-26 08:30AM	Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL(Benzgalantamine) Use in Long-Term Care (Business Wire)
Sep-09-26 06:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:00PM	Loading…
Sep-01-26 05:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-17-26 10:43AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26 (Newsfile)
Aug-13-26 04:05PM	Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update (Business Wire)
Aug-03-26 08:30AM	Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update (Business Wire)
Jul-29-26 08:30AM	Alpha Cognition Receives European Patent Covering ZUNVEYL for the Treatment of Mild-to-Moderate Alzheimer's Disease (Business Wire)
Jul-10-26 08:30AM	Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit (Business Wire)
Jun-23-26 08:30AM	Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board (Business Wire)
Jun-09-26 08:00AM	Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL in Alzheimers Disease (Business Wire)
May-14-26 04:15PM	Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update (Business Wire) +5.99%
Apr-28-26 04:30PM	Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026 (Business Wire) -5.32%
08:00AM	Loading…
Apr-27-26 08:00AM	Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences (Business Wire) -6.20%
Apr-20-26 05:00PM	Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig (Business Wire)
Apr-15-26 08:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-26 04:21PM	Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock? (Quartz)
Apr-01-26 04:30PM	Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury (Business Wire) +8.56%
09:51AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425 (Newsfile)
Mar-26-26 04:01PM	Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update (Business Wire)
Mar-13-26 01:46PM	Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 (Business Wire)
Mar-10-26 08:30AM	Alpha Cognition to Present New Clinical on ZUNVEYL (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences (Business Wire)
Feb-25-26 08:30AM	Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study (Business Wire) +5.41%
Feb-18-26 08:30AM	Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL Dosing Regimens (Business Wire) +11.32%
Jan-07-26 04:30PM	Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution (Business Wire) +5.18%
Dec-05-25 09:40AM	Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? (Zacks)
Dec-01-25 05:51PM	Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners (Business Wire) -6.15%
Nov-19-25 09:41AM	Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:46AM	Loading…
Nov-14-25 09:46AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025 (Newsfile)
Nov-13-25 06:40PM	Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Nov-12-25 07:54AM	MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
07:30AM	Alpha Cognition Inc (ACOG) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-30-25 08:30AM	Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025 (Business Wire) -5.94%
Oct-15-25 09:00AM	Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference (NewMediaWire)
Oct-14-25 04:30PM	Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings (Business Wire)
Oct-06-25 08:30AM	Alpha Cognition to Present Clinical Data at ASCP Annual Meeting (Business Wire)
Sep-30-25 11:14PM	Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares (Business Wire) +13.21%
04:58PM	Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares (Business Wire)
Aug-28-25 01:00PM	Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences (Business Wire)
Aug-15-25 05:10PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025 (Newsfile) +5.56%
Aug-14-25 06:55PM	Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -19.92%
08:30AM	Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Aug-04-25 08:30AM	Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Jul-29-25 08:30AM	Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL (Benzgalantamine) for Alzheimers Disease (Business Wire)
Jul-08-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Study Data at Alzheimers Association International Conference (Business Wire) -5.07%
Jul-04-25 12:00PM	What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock (Zacks)
Jul-01-25 05:05PM	Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire) +16.20%
09:40AM	Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-16-25 09:55AM	Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross? (Zacks)
Jun-06-25 04:31PM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
May-19-25 10:25AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 (Newsfile) +15.61%
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +27.02%
08:30AM	Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview (Business Wire)
May-01-25 08:30AM	Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview (Business Wire) +8.33%
Apr-30-25 07:30AM	Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference (Business Wire)
Apr-10-25 08:30AM	Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens (Business Wire)
Apr-01-25 04:27PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 (Newsfile)
Mar-31-25 09:50PM	Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript (Seeking Alpha) -8.50%
08:30AM	Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-19-25 04:30PM	Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-18-25 08:30AM	Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease (Business Wire)
Mar-05-25 08:35AM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
Feb-12-25 08:30AM	Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimers disease (Business Wire)
Jan-30-25 11:05AM	Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) (Newsfile) -5.06%
Jan-22-25 07:00AM	OTC Markets Group Announces Quarterly Index Performance and Rebalancing (GlobeNewswire)
Jan-14-25 08:30AM	Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL (Business Wire)
Jan-08-25 08:30AM	Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimers Disease, in China (Business Wire)
Jan-06-25 08:30AM	Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call (Business Wire)
Dec-16-24 02:56PM	Alpha Cognition Announces Partial Exercise of Over-allotment Option (Business Wire) -11.62%
Dec-12-24 06:41PM	Alpha Cognition Announces Voluntary Delisting from CSE (Business Wire) -5.57%
Dec-11-24 08:30AM	Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire)
Nov-15-24 05:00PM	Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update (Business Wire) -5.38% +6.15%
Nov-12-24 09:22AM	Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing (Business Wire) -32.14%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Oct 15 '26	Buy	8.43	22,657	190,974	3,245,611	Oct 19 05:34 PM
Opaleye Management Inc.	10% Owner	Oct 16 '26	Buy	8.23	14,283	117,602	3,259,894	Oct 19 05:34 PM
Opaleye Management Inc.	10% Owner	Oct 01 '26	Buy	8.69	19,050	165,634	3,222,954	Oct 02 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 24 '26	Buy	8.57	18,337	157,082	3,190,478	Sep 28 07:57 PM
Opaleye Management Inc.	10% Owner	Sep 25 '26	Buy	8.47	13,426	113,718	3,203,904	Sep 28 07:57 PM
Opaleye Management Inc.	10% Owner	Sep 16 '26	Buy	8.51	80,170	682,591	3,172,141	Sep 16 05:57 PM
Opaleye Management Inc.	10% Owner	Sep 14 '26	Buy	8.70	40,373	351,084	3,088,596	Sep 16 05:57 PM
Opaleye Management Inc.	10% Owner	Sep 15 '26	Buy	8.54	3,375	28,831	3,091,971	Sep 16 05:57 PM
Wills Robert James	Director	Aug 21 '26	Buy	9.62	10,000	96,200	32,241	Aug 24 02:52 PM
Opaleye Management Inc.	10% Owner	Aug 03 '26	Buy	8.00	50,000	400,000	3,048,223	Aug 04 04:50 PM
Opaleye Management Inc.	10% Owner	Jul 31 '26	Buy	7.92	2,900	22,976	2,998,223	Aug 04 04:50 PM
Opaleye Management Inc.	10% Owner	Jul 24 '26	Buy	7.90	130	1,027	2,995,323	Jul 28 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 22 '26	Buy	7.83	150,237	1,176,912	2,945,344	Jul 24 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 23 '26	Buy	7.80	49,849	388,588	2,995,193	Jul 24 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 26 '26	Buy	6.40	152,336	975,209	2,805,107	Jun 29 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 25 '26	Buy	6.50	197	1,280	2,652,771	Jun 29 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 15 '26	Buy	5.99	4,550	27,253	2,652,574	Jun 15 08:10 PM
Opaleye Management Inc.	10% Owner	Jun 11 '26	Buy	5.91	2,862	16,901	2,647,751	Jun 15 08:10 PM
Opaleye Management Inc.	10% Owner	Jun 12 '26	Buy	5.93	273	1,619	2,648,024	Jun 15 08:10 PM
Opaleye Management Inc.	10% Owner	Jun 09 '26	Buy	5.98	24,856	148,534	2,639,017	Jun 11 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 10 '26	Buy	5.99	5,872	35,157	2,644,889	Jun 11 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 05 '26	Buy	5.83	10,054	58,596	2,614,161	Jun 09 04:05 PM
Opaleye Management Inc.	10% Owner	May 29 '26	Buy	5.90	70,577	416,397	2,604,107	May 29 07:21 PM
Opaleye Management Inc.	10% Owner	May 28 '26	Buy	5.83	2,000	11,664	2,533,530	May 29 07:21 PM
Opaleye Management Inc.	10% Owner	May 27 '26	Buy	5.73	1,161	6,653	2,531,530	May 29 07:21 PM
Opaleye Management Inc.	10% Owner	May 21 '26	Buy	5.70	15,945	90,886	2,530,369	May 22 04:05 PM
Opaleye Management Inc.	10% Owner	May 20 '26	Buy	5.89	8,431	49,659	2,514,424	May 22 04:05 PM
D'Angelo Lauren	Chief Operating Officer	May 19 '26	Buy	5.76	3,500	20,160	140,695	May 19 05:02 PM
Opaleye Management Inc.	10% Owner	May 18 '26	Buy	5.69	17,395	99,023	2,505,993	May 19 04:05 PM
Opaleye Management Inc.	10% Owner	May 15 '26	Buy	5.83	16,648	96,986	2,488,598	May 19 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 27 '26	Buy	5.08	10,000	50,792	2,470,000	Mar 31 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 30 '26	Buy	4.99	1,850	9,227	2,471,850	Mar 31 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 25 '26	Buy	5.43	8,581	46,579	2,452,681	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 26 '26	Buy	5.28	7,319	38,675	2,460,000	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 24 '26	Buy	5.59	4,182	23,377	2,444,100	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 18 '26	Buy	5.75	2,481	14,263	2,437,824	Mar 20 04:54 PM
Opaleye Management Inc.	10% Owner	Mar 19 '26	Buy	5.71	2,094	11,950	2,439,918	Mar 20 04:54 PM
Opaleye Management Inc.	10% Owner	Mar 16 '26	Buy	5.78	1,331	7,696	2,435,343	Mar 18 06:55 PM
Opaleye Management Inc.	10% Owner	Mar 13 '26	Buy	5.75	7,358	42,286	2,434,012	Mar 13 06:43 PM
Opaleye Management Inc.	10% Owner	Mar 12 '26	Buy	5.85	5,708	33,416	2,426,654	Mar 13 06:43 PM
Opaleye Management Inc.	10% Owner	Mar 09 '26	Buy	5.85	2,179	12,742	2,420,946	Mar 10 06:47 PM
Opaleye Management Inc.	10% Owner	Mar 06 '26	Buy	5.80	1,900	11,018	2,418,767	Mar 10 06:47 PM
Opaleye Management Inc.	10% Owner	Mar 05 '26	Buy	5.80	47,023	272,621	2,416,867	Mar 06 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 04 '26	Buy	5.81	19,795	115,001	2,374,844	Mar 06 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '26	Buy	5.75	51,411	295,624	2,355,049	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 02 '26	Buy	5.80	20,000	116,000	2,308,638	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 27 '26	Buy	5.99	3,638	21,797	2,288,638	Mar 02 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 26 '26	Buy	5.99	590	3,531	2,285,000	Mar 02 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 23 '26	Buy	5.89	100,000	589,230	2,230,819	Feb 24 05:52 PM
Opaleye Management Inc.	10% Owner	Feb 24 '26	Buy	5.80	58,591	339,851	2,284,410	Feb 24 05:52 PM
Opaleye Management Inc.	10% Owner	Feb 20 '26	Buy	5.84	12,819	74,877	2,135,000	Feb 24 05:52 PM

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal ("ALPHA-1062IN") formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

CEO & DirectorMr. Michael E. McFadden B.B.A.

LL.B.Mr. Kenneth Anthony Cawkell B.A.

VP of Finance & Accounting and Interim CFOMr. Henry H. Du CPA

Chief Operating OfficerMs. Lauren D'Angelo M.B.A.

Ph.D.Dr. Denis G. Kay M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACOG

Alpha Cognition Inc

Upgrade your Finviz experience